It was further shown that genetic ablation or pharmacological inhibition of SLC7A11 markedly attenuates oncogenic KRAS-induced tumor growth in xenograft models (Lim et al., 2019; Hu et al., 2020). This evidence concerns the gene SLC7A11 and neoplasm.